601607 上海医药
交易中 12-19 13:48:26
资讯
新帖
简况
【港股通】上海医药(02607)拟用于治疗精神分裂症的创新药“I048”临床试验申请获批
金吾财讯 · 12-18 17:32
【港股通】上海医药(02607)拟用于治疗精神分裂症的创新药“I048”临床试验申请获批
上海医药(02607.HK)旗下治疗精神分裂症药物获批临床
阿斯达克财经 · 12-18 17:14
上海医药(02607.HK)旗下治疗精神分裂症药物获批临床
上海医药(02607)：“I048 ”获得临床试验批准通知书
智通财经 · 12-18 17:05
上海医药(02607)：“I048 ”获得临床试验批准通知书
上海医药(02607)出现大手卖出39.58万股，成交价$13.14，涉资520.081万
阿斯达克财经 · 12-18 16:08
上海医药(02607)出现大手卖出39.58万股，成交价$13.14，涉资520.081万
上海医药(601607.SH)：I048片开展精神分裂症的临床试验获批
智通财经 · 12-18 15:35
上海医药(601607.SH)：I048片开展精神分裂症的临床试验获批
上海医药12月18日主力资金流出1111万元 连续5日减仓
市场透视 · 12-18 15:20
上海医药12月18日主力资金流出1111万元 连续5日减仓
上海医药12月16日主力资金流出205万元 连续3日减仓
市场透视 · 12-16 15:18
上海医药12月16日主力资金流出205万元 连续3日减仓
上海医药(02607.HK)旗下治疗下肢浅静脉曲张等注射液获批临床
阿斯达克财经 · 12-11
上海医药(02607.HK)旗下治疗下肢浅静脉曲张等注射液获批临床
上海医药(02607)：十四烷基硫酸钠注射液获得临床试验批准通知书
智通财经 · 12-11
上海医药(02607)：十四烷基硫酸钠注射液获得临床试验批准通知书
上海医药(601607.SH)：十四烷基硫酸钠注射液获得临床试验批准通知书
智通财经 · 12-11
上海医药(601607.SH)：十四烷基硫酸钠注射液获得临床试验批准通知书
上海医药：全资子公司收到十四烷基硫酸钠注射液临床试验批准通知书
美港电讯 · 12-11
上海医药：全资子公司收到十四烷基硫酸钠注射液临床试验批准通知书
《股市简讯》上海医药A/H股齐升逾2%，子公司药物获美国FDA孤儿药资格认定
路透中文 · 12-11
《股市简讯》上海医药A/H股齐升逾2%，子公司药物获美国FDA孤儿药资格认定
金十数据整理：每日港股市场要闻速递（12月11日 周三）
美港电讯 · 12-11
金十数据整理：每日港股市场要闻速递（12月11日 周三）
未来三年并购激活两万亿资产，上海重点支持三大先导产业
第一财经 · 12-10
未来三年并购激活两万亿资产，上海重点支持三大先导产业
【港股通】上海医药(02607)SRD4610获得美国FDA孤儿药资格认定
金吾财讯 · 12-10
【港股通】上海医药(02607)SRD4610获得美国FDA孤儿药资格认定
上海医药(02607.HK)旗下复方中药创新药获FDA孤儿药资格认定
阿斯达克财经 · 12-10
上海医药(02607.HK)旗下复方中药创新药获FDA孤儿药资格认定
上海医药(02607)：SRD4610获得美国FDA孤儿药资格认定
智通财经 · 12-10
上海医药(02607)：SRD4610获得美国FDA孤儿药资格认定
上海医药(601607.SH)：SRD4610用于肌萎缩侧索硬化症(ALS)适应症获美国FDA孤儿药资格认定
智通财经 · 12-10
上海医药(601607.SH)：SRD4610用于肌萎缩侧索硬化症(ALS)适应症获美国FDA孤儿药资格认定
上海医药12月09日主力资金流出2204万元 连续3日减仓
市场透视 · 12-09
上海医药12月09日主力资金流出2204万元 连续3日减仓
上海医药12月06日遭主力抛售1247万元 环比增加130.07%
市场透视 · 12-06
上海医药12月06日遭主力抛售1247万元 环比增加130.07%
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司主营业务为医药研发与制造、分销与零售。主要产品为丹参酮ⅡA磺酸钠注射液、注射用乌司他丁、硫酸羟氯喹片、注射用二丁酰环磷腺苷钙、注射用盐酸头孢替安、丹参片、参麦注射液、瓜蒌皮注射液、尪痹片、银杏酮酯等。集团在证券之星、第一财经以及上海市股份公司联合会共举办的"上海上市公司评选"中荣获"最佳转型奖"。中国医药上市公司竞争力50强榜首,中国医药行业"十大最具影响力企业"之一,"投资者关系管理百强";荣列上海企业100强第19位、上海制造业企业50强第9位、中国企业500强第203位、中国制造业企业500强第99位、中国制药工业百强第3位等。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":21.62,"timestamp":1734587306000,"preClose":21.63,"halted":0,"volume":5209182,"delay":0,"floatShares":1936000000,"shares":3708000000,"eps":1.0858,"marketStatus":"交易中","marketStatusCode":2,"change":-0.01,"latestTime":"12-19 13:48:26","open":21.5,"high":21.69,"low":21.35,"amount":112000000,"amplitude":0.0157,"askPrice":21.62,"askSize":55,"bidPrice":21.61,"bidSize":141,"shortable":0,"etf":0,"ttmEps":1.0858,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734591600000},"adr":0,"adjPreClose":21.63,"symbolType":"stock","openAndCloseTimeList":[[1734571800000,1734579000000],[1734584400000,1734591600000]],"highLimit":23.79,"lowLimit":19.47,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3707656001,"pbRate":1.13,"roa":"--","roe":"5.74%","epsLYR":1.02,"committee":0.580161,"marketValue":80160000000,"floatMarketCap":41854000000,"peRate":19.911585,"changeRate":-0.0005,"turnoverRate":0.0027,"status":1},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2492932908","title":"【港股通】上海医药(02607)拟用于治疗精神分裂症的创新药“I048”临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932908","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932908?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:32","pubTimestamp":1734514347,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海医药(02607)，集团开发的“I048”临床试验申请收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。该项目由上海医药集团股份有限公司主导研发，公司拥有全球独占实施许可权益。截至目前，该项目已累计投入研发费用为2,516.30万元人民币。截至本公告日，全球未有完全相同靶点和同适应症的药品上市。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","BK0020","BK0097","HSTECH","BK0175","BK0028","BK1583","BK0099","BK0209","601607","02607","BK1197","BK0184","06978","BK0187","BK0188","BK0183","159992","03347","BK1161","BK1141","BK0012","BK1574","BK0196","HSCEI","YANG"],"gpt_icon":0},{"id":"2492097725","title":"上海医药(02607.HK)旗下治疗精神分裂症药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2492097725","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492097725?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:14","pubTimestamp":1734513240,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 公布，近日公司开发的I048临床试验申请收到国家药监局核准签发的《药物临床试验批准通知书》。I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。 (ha/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-18 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210429113037512_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405006/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0188","BK0183","BK0028","BK0196","BK0099","BK0020","BK0209","BK0097","601607","02607","BK0012","BK1197","BK0184","BK0187","BK0175"],"gpt_icon":0},{"id":"2492725789","title":"上海医药(02607)：“I048 ”获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2492725789","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492725789?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:05","pubTimestamp":1734512707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，该公司开发的“I048”临床试验申请收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。I048 是小分子一类新药，拟用于治疗精神分裂症。该项目由上海医药集团股份有限公司主导研发，公司拥有全球独占实施许可权益。截至目前，该项目已累计投入研发费用为 2516.30 万元人民币。公司本次申报的“I048”需完成临床试验并经国家药监局批准后方可上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0020","BK0097","BK0175","BK0028","BK1583","BK0099","BK0209","601607","02607","BK1197","BK0184","BK0187","BK0188","BK0183","03347","BK1141","BK0012","BK0196"],"gpt_icon":0},{"id":"2492269971","title":"上海医药(02607)出现大手卖出39.58万股，成交价$13.14，涉资520.081万","url":"https://stock-news.laohu8.com/highlight/detail?id=2492269971","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492269971?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:08","pubTimestamp":1734509280,"startTime":"0","endTime":"0","summary":"[大手成交]上海医药(02607)在下午04:08出现大手卖出，成交量为39.58万，成交价为港币$13.14，涉资520.081万。至目前为止，股价升1.233%，今日最高价为$13.24，而最低价为$12.98，总成交量为334.05万股，总成交金额港币$4.391千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2412184128/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02607","BK0097","BK0188","601607","BK0020","BK0196","BK0209","BK0184","BK1197","BK0099","BK0183","BK0187","BK0012","BK0175","BK0028"],"gpt_icon":0},{"id":"2492975851","title":"上海医药(601607.SH)：I048片开展精神分裂症的临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2492975851","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492975851?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:35","pubTimestamp":1734507343,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司开发的“I048”(以下简称“该项目”)临床试验申请收到国家药品监督管理局(以下简称“国家药监局”)核准签发的《药物临床试验批准通知书》，经审查，2024年11月21日受理的I048片临床试验申请符合药品注册的有关要求，同意开展精神分裂症的临床试验。据悉，I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。该项目由上海医药集团股份有限公司主导研发，公司拥有全球独占实施许可权益。截至目前，该项目已累计投入研发费用为2,516.30万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK1141","03347","BK1197","BK0184","BK0028","BK0196","BK0175","BK0187","BK0012","BK0183","BK0097","BK1583","BK0020","601607","BK0209","BK0188","BK0099","BK1576"],"gpt_icon":0},{"id":"2492908528","title":"上海医药12月18日主力资金流出1111万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2492908528","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492908528?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:20","pubTimestamp":1734506422,"startTime":"0","endTime":"0","summary":"12月18日, 上海医药股价涨1.03%，报收21.63元，成交金额1.51亿元，换手率0.36%，振幅1.45%，量比0.46。上海医药今日主力资金净流出1111万元，连续5日净流出，上一交易日主力净流出1233万元，今日环比减少9.89%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为37.50%，平均跌幅为0.53%。该股近5个交易日下跌1.37%，主力资金累计净流出7444万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2.97亿元，其中净流出天数为18日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218154457a1f7ebd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218154457a1f7ebd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","BK0209","BK0028","601607","BK0183","BK0187","BK0196","BK0020","BK0012","BK0099","BK0184","BK0188","BK0097"],"gpt_icon":0},{"id":"2491156496","title":"上海医药12月16日主力资金流出205万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491156496","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491156496?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:18","pubTimestamp":1734333528,"startTime":"0","endTime":"0","summary":"12月16日, 上海医药股价跌0.83%，报收21.56元，成交金额2.15亿元，换手率0.51%，振幅1.75%，量比0.59。上海医药今日主力资金净流出205万元，连续3日净流出，上一交易日主力净流出1914万元，今日环比减少89.29%。该股近5个交易日下跌0.05%，主力资金累计净流出6152万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2.19亿元，其中净流出天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216152724ab7bab60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216152724ab7bab60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601607","BK0184","BK0099","BK0175","BK0209","BK0012","BK0183","BK0097","BK0188","BK0196","BK0028","BK0187","BK0020"],"gpt_icon":0},{"id":"2490833065","title":"上海医药(02607.HK)旗下治疗下肢浅静脉曲张等注射液获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2490833065","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490833065?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:08","pubTimestamp":1733908080,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 公布，全资子公司上药第一生化收到国家药监局核准签发的关于十四烷基硫酸钠注射液的《药物临床试验批准通知书》，将于近期启动Ⅰ期临床试验。公司指，十四烷基硫酸钠是一种硬化剂，拟用于治疗无并发症的原发性下肢浅静脉曲张、术后复发或残留的静脉曲张及简单扩张的下肢网状静脉，小静脉和蜘蛛状静脉。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-11 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210429113037816_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210429113037816_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403403/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0183","BK0188","BK0184","BK0196","BK0187","601607","BK0099","BK0209","BK1197","02607","BK0020","BK0175","BK0097","BK0028","BK0012"],"gpt_icon":0},{"id":"2490083373","title":"上海医药(02607)：十四烷基硫酸钠注射液获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490083373","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490083373?lang=zh_cn&edition=full","pubTime":"2024-12-11 17:05","pubTimestamp":1733907934,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，上海医药集团股份有限公司(以下简称“上海医药”或“公司”)全资子公司上海上药第一生化药业有限公司(以下简称“上药第一生化”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发的关于十四烷基硫酸钠注射液(以下简称“该项目”)的《药物临床试验批准通知书》(通知书编号： 2024LP02466、2024LP02467)，将于近期启动Ⅰ期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0209","03347","601607","BK0175","BK0196","BK0028","BK1576","BK0184","BK1141","BK0187","BK1197","BK0183","BK0099","BK0020","02607","BK0012","BK0188","BK0097"],"gpt_icon":0},{"id":"2490846588","title":"上海医药(601607.SH)：十四烷基硫酸钠注射液获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490846588","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490846588?lang=zh_cn&edition=full","pubTime":"2024-12-11 15:35","pubTimestamp":1733902535,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司全资子公司上海上药第一生化药业有限公司(简称“上药第一生化”)收到国家药品监督管理局核准签发的关于十四烷基硫酸钠注射液的《药物临床试验批准通知书》(通知书编号：2024LP02466、2024LP02467)，将于近期启动Ⅰ期临床试验。十四烷基硫酸钠是一种硬化剂，拟用于治疗无并发症的原发性下肢浅静脉曲张、术后复发或残留的静脉曲张及简单扩张的下肢网状静脉，小静脉和蜘蛛状静脉。十四烷基硫酸钠注射后化学刺激性小，不产生剧烈疼痛，无醉酒样反应等，具有疗效确切、安全性好等优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02607","BK0196","BK0183","BK0187","BK0028","BK0097","BK1141","BK1576","BK0184","BK1197","BK0012","BK0209","03347","BK0188","BK0020","BK0175","BK0099","601607"],"gpt_icon":0},{"id":"2490288451","title":"上海医药：全资子公司收到十四烷基硫酸钠注射液临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2490288451","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490288451?lang=zh_cn&edition=full","pubTime":"2024-12-11 15:35","pubTimestamp":1733902513,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0183","BK0097","601607","BK0184","BK0196","03347","BK0020","BK0187","02607","BK1141","BK1576","BK0175","BK0028","BK1583","BK0188","BK0099","BK0209","BK1197","BK0012"],"gpt_icon":0},{"id":"2490702450","title":"《股市简讯》上海医药A/H股齐升逾2%，子公司药物获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490702450","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490702450?lang=zh_cn&edition=full","pubTime":"2024-12-11 10:09","pubTimestamp":1733882991,"startTime":"0","endTime":"0","summary":"《股市简讯》上海医药A/H股齐升逾2%，子公司药物获美国FDA孤儿药资格认定* 上海政府旗下经营药物研发与连锁药房的上海医药601607.SS2607.HKA/H股周三早盘均涨超2%。* 上海医药公告称，全资子公司上药睿尔自主研发的 SRD4610用于肌萎缩侧索硬化症（ALS）适应症获得美国食品药品监督管理局（FDA）孤儿药资格认定（Orphan-drug Designation）。（完） 更多股市简讯请点选CN-CMN-HOT (发稿 刘珞焱；审校 田镧沁) ((luoyan.liu@tr.com; +86 021 2083 0166;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nL4S3NC04L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601607","BK0175","BK1550","BK0184","BK0188","BK0187","BK0196","BK1584","SG9999006597.SGD","BK1184","BK0099","BK0183","BK0028","BK1197","02607","BK0207","BK0020","BK0209","BK0012","601336","01336","BK0097"],"gpt_icon":0},{"id":"2490074179","title":"金十数据整理：每日港股市场要闻速递（12月11日 周三）","url":"https://stock-news.laohu8.com/highlight/detail?id=2490074179","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490074179?lang=zh_cn&edition=full","pubTime":"2024-12-11 09:12","pubTimestamp":1733879569,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["00020","BK1521","07226","BK0188","SG9999012728.SGD","BK1115","BK0187","00776","00754","BK1604","BK0209","BK1164","01025","BK1197","BK0020","BK1184","BK1550","BK0012","80020","BK1584","BK0207","SG9999012736.USD","SG9999012710.SGD","01813","01628","BK0184","BK1555","02999","SG9999012744.USD","BK0099","601628","BK1240","02607","BK1227","HSCEI","BK0097","BK1109","BK0028","01992","BK1135","LU1046422090.SGD","BK0196","02628","IE0032431581.USD","YANG","LU0588546209.SGD","BK0175","601607","BK1149","HSTECH"],"gpt_icon":0},{"id":"2490154830","title":"未来三年并购激活两万亿资产，上海重点支持三大先导产业","url":"https://stock-news.laohu8.com/highlight/detail?id=2490154830","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490154830?lang=zh_cn&edition=full","pubTime":"2024-12-10 21:44","pubTimestamp":1733838240,"startTime":"0","endTime":"0","summary":"上海444家上市公司迎来并购重组政策支持。12月10日，上海市政府印发《上海市支持上市公司并购重组行动方案》，共计12条，全面支持上市公司通过并购重组做大做强，重点支持三大先导产业。 Wind数据显示，截至12月10日，上海上市公司共计444家，总市值9.38万亿元，其中有161家百亿市值公司、17家千亿市值公司，中芯国际市值排名第一。由于国资背景的公司具有重组的先天优势，87家上海地方国企下一步的并购计划将是市场关注的焦点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-12-10/doc-incyyxsi4696477.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-12-10/doc-incyyxsi4696477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600119","BK0070","688336","BK0097","BK0239","601156","LU2211815571.USD","BK0099","BK0276","688578","BK0184","BK0251","BK0096","159982","688012","600837","LU1064131003.USD","LU2148510915.USD","603648","BK0125","BK0139","600196","688271","BK0060","LU2289578879.USD","688180","BK0209","603329","BK0011","BK0234","688981","BK0210","BK0214","LU1997245177.USD","601211","SG9999014674.SGD","BK0028","688615","603501","LU1997245094.SGD","BK0280","BK0187","BK0020","BK0201","399300","601607","BK0196","LU1328615791.USD","BK0183","688347"],"gpt_icon":0},{"id":"2490064449","title":"【港股通】上海医药(02607)SRD4610获得美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490064449","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490064449?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:17","pubTimestamp":1733822271,"startTime":"0","endTime":"0","summary":"金吾财讯｜上海医药(02607)公布，全资子公司上海上药睿尔药品有限公司自主研发的SRD4610用于肌萎缩侧索硬化症(ALS)适应症获得美国食品药品监督管理局(“美国FDA”)孤儿药资格认定(Orphan-drug Designation)。据悉，SRD4610是一种复方中药创新药，目前该项目已在国内完成针对肌萎缩侧索硬化症的Ⅱ期临床试验。该项目由上海医药自主研发，公司拥有完全知识产权。截至本公告日，该项目在全球已累计投入研发费用约人民币6,542万元。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/YWMzMDYxNjliM2VjNmQwMDUwODkzNDE4MTMw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YWMzMDYxNjliM2VjNmQwMDUwODkzNDE4MTMw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949356","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","02607","601607","BK0099","BK0184","BK0188","BK0012","BK0196","BK0097","BK0183","BK0175","HSCEI","BK1197","HSTECH","BK0020","BK0028","YANG","BK0209"],"gpt_icon":0},{"id":"2490062706","title":"上海医药(02607.HK)旗下复方中药创新药获FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490062706","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490062706?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:07","pubTimestamp":1733821620,"startTime":"0","endTime":"0","summary":"上海医药(02607.HK) 全资子公司上药睿尔自主研发的SRD4610用于肌萎缩侧索硬化症适应症获得美国食品药品监督管理局孤儿药资格认定。SRD4610是一种复方中药创新药，目前该项目已在国内完成针对肌萎缩侧索硬化症的Ⅱ期临床试验。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-10 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180202161553962_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180202161553962_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1403087/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0175","BK0012","BK0187","BK0097","601607","BK0099","BK0209","BK0020","02607","BK0028","BK0196","BK0188","BK1197","BK0184","BK0183","06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2490064819","title":"上海医药(02607)：SRD4610获得美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490064819","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490064819?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:05","pubTimestamp":1733821534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，该公司全资子公司上海上药睿尔药品有限公司自主研发的SRD4610用于肌萎缩侧索硬化症适应症获得美国食品药品监督管理局孤儿药资格认定。据悉，SRD4610是一种复方中药创新药，目前该项目已在国内完成针对肌萎缩侧索硬化症的Ⅱ期临床试验。截至本公告日，没有同靶点的产品获得FDA批准上市以治疗ALS。本次获得美国FDA的孤儿药认定，能够加快推进临床试验及上市注册的进度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0187","BK0196","BK0099","BK0028","601607","BK0020","BK0184","02607","BK0188","BK0097","BK0175","BK1197","BK0012","BK0183"],"gpt_icon":0},{"id":"2490917065","title":"上海医药(601607.SH)：SRD4610用于肌萎缩侧索硬化症(ALS)适应症获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2490917065","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490917065?lang=zh_cn&edition=full","pubTime":"2024-12-10 15:52","pubTimestamp":1733817157,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，公司全资子公司上海上药睿尔药品有限公司自主研发的SRD4610用于肌萎缩侧索硬化症适应症获得美国食品药品监督管理局孤儿药资格认定。据悉，SRD4610是一种复方中药创新药，目前该项目已在国内完成针对肌萎缩侧索硬化症的Ⅱ期临床试验。截至本公告日，该项目在全球已累计投入研发费用约人民币6,542万元。本次获得美国FDA的孤儿药认定，能够加快推进临床试验及上市注册的进度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","02607","BK0175","BK1197","BK0184","BK0196","BK0099","BK0012","601607","BK0209","BK0028","BK0097","BK0020","BK0188","BK0183"],"gpt_icon":0},{"id":"2490712539","title":"上海医药12月09日主力资金流出2204万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2490712539","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490712539?lang=zh_cn&edition=full","pubTime":"2024-12-09 15:19","pubTimestamp":1733728750,"startTime":"0","endTime":"0","summary":"12月09日, 上海医药股价跌0.74%，报收21.57元，成交金额2.15亿元，换手率0.51%，振幅2.16%，量比0.57。上海医药今日主力资金净流出2204万元，连续3日净流出，上一交易日主力净流出1247万元，今日环比增加76.74%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为22.73%，平均跌幅为0.85%。该股近5个交易日上涨1.27%，主力资金累计净流出4310万元；近20日主力资金累计净流出7892万元，其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209152827a1dfbdda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209152827a1dfbdda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601607","BK0175","BK0012","BK0020","BK0188","BK0099","BK0183","BK0209","BK0028","BK0184","BK0097","BK0187","BK0196"],"gpt_icon":0},{"id":"2489286920","title":"上海医药12月06日遭主力抛售1247万元 环比增加130.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489286920","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489286920?lang=zh_cn&edition=full","pubTime":"2024-12-06 15:18","pubTimestamp":1733469496,"startTime":"0","endTime":"0","summary":"12月06日, 上海医药股价涨2.26%，报收21.73元，成交金额4.95亿元，换手率1.18%，振幅2.96%，量比1.40。上海医药今日主力资金净流出1247万元，上一交易日主力净流出542万元，今日环比增加130.07%。该股近5个交易日下跌0.09%，主力资金累计净流出5894万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入1480万元，其中净流入天数为7日。净流出前三个股分别为中国医药、上海医药、大参林。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206152221ab61e7c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206152221ab61e7c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0020","BK0028","BK0012","BK0175","BK0183","BK0097","BK0209","BK0187","601607","BK0188","BK0196","BK0099","BK0184"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","stockEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0444},{"period":"3month","weight":0.1387},{"period":"6month","weight":0.1658},{"period":"1year","weight":0.3423},{"period":"ytd","weight":0.3254}],"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","perCapita":"29358股","boardName":"零售业","registeredCapital":"370765万元","compareEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.2362},{"period":"6month","weight":0.1281},{"period":"1year","weight":0.1534},{"period":"ytd","weight":0.1369}],"survey":" 上海医药集团股份有限公司主营业务为医药研发与制造、分销与零售。主要产品为丹参酮ⅡA磺酸钠注射液、注射用乌司他丁、硫酸羟氯喹片、注射用二丁酰环磷腺苷钙、注射用盐酸头孢替安、丹参片、参麦注射液、瓜蒌皮注射液、尪痹片、银杏酮酯等。集团在证券之星、第一财经以及上海市股份公司联合会共举办的\"上海上市公司评选\"中荣获\"最佳转型奖\"。中国医药上市公司竞争力50强榜首,中国医药行业\"十大最具影响力企业\"之一,\"投资者关系管理百强\";荣列上海企业100强第19位、上海制造业企业50强第9位、中国企业500强第203位、中国制造业企业500强第99位、中国制药工业百强第3位等。","serverTime":1734587315251,"listedPrice":4.5,"stockholders":"65940人(较上一季度增加Infinity%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}